BioCentury
ARTICLE | Clinical News

OGS reports pivotal data

February 12, 2001 8:00 AM UTC

Oxford GlycoSciences (LSE:OGS; OGSI) said preliminary analysis of a six-month, 36-patient pivotal study showed Vevesca oral N-butyldeoxynojirimycin glucosyltransferase inhibitor alone successfully mai...